- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04818398
Study of Single-Ascending Doses of DS-6016a in Healthy Japanese Subjects
August 2, 2022 updated by: Daiichi Sankyo Co., Ltd.
Single-Ascending Dose Phase 1 Study to Assess the Safety, Tolerability, and Pharmacokinetics of DS-6016a After Subcutaneous Injection in Healthy Japanese Subjects
This study will assess the safety, tolerability, and pharmacokinetics of DS-6016a after subcutaneous injection in healthy Japanese participants.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
48
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Osaka, Japan, 532-0003
- Medical Corporation Heishinkai OPHAC Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years to 45 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Male
Description
Inclusion Criteria:
- Japanese healthy male subjects.
- Age ≥20 and ≤45 years upon providing informed consent.
- Body mass index (BMI) ≥18.5 and <25.0 kg/m^2 at screening.
Exclusion Criteria:
- Have a history of hypersensitivity to any drugs or substances, or being idiosyncratic (eg, having penicillin allergy)
- Have alcohol or drug dependence, etc.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: DS-6016a dose level 1
Participants will be randomized to receive a single, subcutaneous injection of DS-6016a.
|
DS-6016a will be administered as a single subcutaneous injection into the upper arm, upper part of the thigh, or abdominal wall
|
Experimental: DS-6016a dose level 2
Participants will be randomized to receive a single, subcutaneous injection of DS-6016a.
|
DS-6016a will be administered as a single subcutaneous injection into the upper arm, upper part of the thigh, or abdominal wall
|
Experimental: DS-6016a dose level 3
Participants will be randomized to receive a single, subcutaneous injection of DS-6016a.
|
DS-6016a will be administered as a single subcutaneous injection into the upper arm, upper part of the thigh, or abdominal wall
|
Experimental: DS-6016a dose level 4
Participants will be randomized to receive a single, subcutaneous injection of DS-6016a.
|
DS-6016a will be administered as a single subcutaneous injection into the upper arm, upper part of the thigh, or abdominal wall
|
Experimental: DS-6016a dose level 5
Participants will be randomized to receive a single, subcutaneous injection of DS-6016a.
|
DS-6016a will be administered as a single subcutaneous injection into the upper arm, upper part of the thigh, or abdominal wall
|
Experimental: DS-6016a dose level 6
Participants will be randomized to receive a single, subcutaneous injection of DS-6016a.
|
DS-6016a will be administered as a single subcutaneous injection into the upper arm, upper part of the thigh, or abdominal wall
|
Placebo Comparator: Placebo
Participants will be randomized to receive a single, subcutaneous injection of placebo.
|
Placebo will be administered as a single subcutaneous injection into the upper arm, upper part of the thigh, or abdominal wall
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number of Participants Reporting Treatment-emergent Adverse Events
Time Frame: Day 1 through end of study, up to 8 weeks post-dose
|
Day 1 through end of study, up to 8 weeks post-dose
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pharmacokinetic Parameter of Maximum (Peak) Observed Serum Concentration (Cmax) of Plasma DS-6016a Following Subcutaneous Administration of DS-6016a
Time Frame: Day 1 (pre-dose, 2 and 8 hours after the start of administration), Day 2 (24 and 36 hours after the start of administration), Day 3, Day 4, Day 5, Day 6, Day 7, Day 8, Day 9, Day 10, Day 12, Day 15, Day 18, Day 22, Day 29, Day 36, Day 43, Day 57
|
Day 1 (pre-dose, 2 and 8 hours after the start of administration), Day 2 (24 and 36 hours after the start of administration), Day 3, Day 4, Day 5, Day 6, Day 7, Day 8, Day 9, Day 10, Day 12, Day 15, Day 18, Day 22, Day 29, Day 36, Day 43, Day 57
|
|
Pharmacokinetic Parameter of Time to Reach Maximum Concentration (Tmax) of Plasma DS-6016a Following Subcutaneous Administration of DS-6016a
Time Frame: Day 1 (pre-dose, 2 and 8 hours after the start of administration), Day 2 (24 and 36 hours after the start of administration), Day 3, Day 4, Day 5, Day 6, Day 7, Day 8, Day 9, Day 10, Day 12, Day 15, Day 18, Day 22, Day 29, Day 36, Day 43, Day 57
|
Day 1 (pre-dose, 2 and 8 hours after the start of administration), Day 2 (24 and 36 hours after the start of administration), Day 3, Day 4, Day 5, Day 6, Day 7, Day 8, Day 9, Day 10, Day 12, Day 15, Day 18, Day 22, Day 29, Day 36, Day 43, Day 57
|
|
Pharmacokinetic Parameter of Area Under the Concentration-time Curve of Plasma DS-6016a Following Subcutaneous Administration of DS-6016a
Time Frame: Day 1 (pre-dose, 2 and 8 hours after the start of administration), Day 2 (24 and 36 hours after the start of administration), Day 3, Day 4, Day 5, Day 6, Day 7, Day 8, Day 9, Day 10, Day 12, Day 15, Day 18, Day 22, Day 29, Day 36, Day 43, Day 57
|
Area under the concentration-time curve from time 0 to last measurable time point (AUClast), time 0 to 336h (AUC336h), and time 0 to infinity (AUCinf) will be assessed.
|
Day 1 (pre-dose, 2 and 8 hours after the start of administration), Day 2 (24 and 36 hours after the start of administration), Day 3, Day 4, Day 5, Day 6, Day 7, Day 8, Day 9, Day 10, Day 12, Day 15, Day 18, Day 22, Day 29, Day 36, Day 43, Day 57
|
Pharmacokinetic Parameter of Total Clearance (CL/F) of Plasma DS-6016a Following Subcutaneous Administration of DS-6016a
Time Frame: Day 1 (pre-dose, 2 and 8 hours after the start of administration), Day 2 (24 and 36 hours after the start of administration), Day 3, Day 4, Day 5, Day 6, Day 7, Day 8, Day 9, Day 10, Day 12, Day 15, Day 18, Day 22, Day 29, Day 36, Day 43, Day 57
|
Day 1 (pre-dose, 2 and 8 hours after the start of administration), Day 2 (24 and 36 hours after the start of administration), Day 3, Day 4, Day 5, Day 6, Day 7, Day 8, Day 9, Day 10, Day 12, Day 15, Day 18, Day 22, Day 29, Day 36, Day 43, Day 57
|
|
Pharmacokinetic Parameter of Terminal elimination half-life (t1/2) of Plasma DS-6016a Following Subcutaneous Administration of DS-6016a
Time Frame: Day 1 (pre-dose, 2 and 8 hours after the start of administration), Day 2 (24 and 36 hours after the start of administration), Day 3, Day 4, Day 5, Day 6, Day 7, Day 8, Day 9, Day 10, Day 12, Day 15, Day 18, Day 22, Day 29, Day 36, Day 43, Day 57
|
Day 1 (pre-dose, 2 and 8 hours after the start of administration), Day 2 (24 and 36 hours after the start of administration), Day 3, Day 4, Day 5, Day 6, Day 7, Day 8, Day 9, Day 10, Day 12, Day 15, Day 18, Day 22, Day 29, Day 36, Day 43, Day 57
|
|
Pharmacokinetic Parameter of Volume of Distribution (Vz/F) of Plasma DS-6016a Following Subcutaneous Administration of DS-6016a
Time Frame: Day 1 (pre-dose, 2 and 8 hours after the start of administration), Day 2 (24 and 36 hours after the start of administration), Day 3, Day 4, Day 5, Day 6, Day 7, Day 8, Day 9, Day 10, Day 12, Day 15, Day 18, Day 22, Day 29, Day 36, Day 43, Day 57
|
Day 1 (pre-dose, 2 and 8 hours after the start of administration), Day 2 (24 and 36 hours after the start of administration), Day 3, Day 4, Day 5, Day 6, Day 7, Day 8, Day 9, Day 10, Day 12, Day 15, Day 18, Day 22, Day 29, Day 36, Day 43, Day 57
|
|
Proportion of Participants Who Are Anti-Drug Antibody (ADA)-Positive (Baseline and Post-Baseline)
Time Frame: Day 1 (pre-dose), Day 29 and Day 57 post-dose
|
The immunogenicity of DS-6016a will be assessed.
|
Day 1 (pre-dose), Day 29 and Day 57 post-dose
|
Proportion of Participants Who Have Treatment-emergent ADAs
Time Frame: Day 1 (pre-dose), Day 29 and Day 57 post-dose
|
The immunogenicity of DS-6016a will be assessed.
|
Day 1 (pre-dose), Day 29 and Day 57 post-dose
|
Proportion of Participants Who Have Anti-host Cell Protein (HCP) Antibodies
Time Frame: Day 1 (pre-dose), Day 29 and Day 57 post-dose
|
The immunogenicity of DS-6016a will be assessed.
|
Day 1 (pre-dose), Day 29 and Day 57 post-dose
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
April 1, 2021
Primary Completion (Actual)
December 24, 2021
Study Completion (Actual)
July 26, 2022
Study Registration Dates
First Submitted
March 24, 2021
First Submitted That Met QC Criteria
March 24, 2021
First Posted (Actual)
March 26, 2021
Study Record Updates
Last Update Posted (Actual)
August 3, 2022
Last Update Submitted That Met QC Criteria
August 2, 2022
Last Verified
August 1, 2022
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- DS6016-A-J101
- jRCT2051200155 (Other Identifier: Japan Registry of Clinical Trial)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Yes
IPD Plan Description
De-identified individual participant data (IPD) and applicable supporting clinical trial documents may be available upon request at https://vivli.org/.
In cases where clinical trial data and supporting documents are provided pursuant to our company policies and procedures, Daiichi Sankyo will continue to protect the privacy of our clinical trial participants.
Details on data sharing criteria and the procedure for requesting access can be found at this web address: https://vivli.org/ourmember/daiichi-sankyo/
IPD Sharing Time Frame
Studies for which the medicine and indication have received European Union (EU) and United States (US), and/or Japan (JP) marketing approval on or after 01 January 2014 or by the US or EU or JP Health Authorities when regulatory submissions in all regions are not planned and after the primary study results have been accepted for publication.
IPD Sharing Access Criteria
Formal request from qualified scientific and medical researchers on IPD and clinical study documents from clinical trials supporting products submitted and licensed in the United States, the European Union and/or Japan from 01 January 2014 and beyond for the purpose of conducting legitimate research.
This must be consistent with the principle of safeguarding study participants' privacy and consistent with provision of informed consent.
IPD Sharing Supporting Information Type
- Study Protocol
- Statistical Analysis Plan (SAP)
- Clinical Study Report (CSR)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Fibrodysplasia Ossificans Progressiva
-
IpsenActive, not recruitingFibrodysplasia Ossificans Progressiva (FOP)United States, France, Australia, Argentina, Italy, Canada, Sweden, United Kingdom, Brazil, Spain
-
Incyte CorporationRecruitingFibrodysplasia Ossificans Progressiva (FOP)United States, France, Korea, Republic of, Spain, United Kingdom, Russian Federation, China, Australia, Brazil, Mexico, Italy, New Zealand, Argentina, Canada, Netherlands, Turkey, Chile, Portugal, Germany, South Africa
-
Clementia Pharmaceuticals Inc.CompletedFibrodysplasia Ossificans ProgressivaUnited States, Canada, France, Australia, Argentina, Brazil, Italy, Japan, Spain, Sweden, United Kingdom
-
Clementia Pharmaceuticals Inc.TerminatedFibrodysplasia Ossificans ProgressivaUnited States
-
The International FOP AssociationRecruitingFibrodysplasia Ossificans Progressiva (FOP)United States
-
Regeneron PharmaceuticalsCompletedFibrodysplasia Ossificans Progressiva (FOP)United States
-
Regeneron PharmaceuticalsCompletedFibrodysplasia Ossificans ProgressivaUnited States, Spain, Canada, France, Poland, Italy, Netherlands, United Kingdom
-
IpsenCompletedFibrodysplasia Ossificans ProgressivaUnited States
-
Novartis PharmaceuticalsCompleted
-
IpsenNot yet recruiting
Clinical Trials on DS-6016a
-
Ludwig Institute for Cancer ResearchDaiichi Sankyo Co., Ltd.; Austin HealthCompletedMalignant Solid Tumor | Metastatic EphA2 Positive CancerAustralia
-
Daiichi Sankyo Co., Ltd.RecruitingSolid Tumor | Metastatic Solid Tumor | Advanced CancerJapan, United States, Canada
-
Daiichi Sankyo Co., Ltd.CompletedAdvanced Solid Malignant TumorsJapan
-
Institut National de la Santé Et de la Recherche...Ultragenyx Pharmaceutical IncCompletedGlut1 Deficiency SyndromeFrance
-
Daiichi Sankyo, Inc.CompletedHepatic ImpairmentUnited States
-
Daiichi Sankyo Co., Ltd.Completed
-
Daiichi Sankyo Co., Ltd.Completed
-
Daiichi Sankyo Co., Ltd.Terminated
-
Daiichi Sankyo Co., Ltd.Recruiting
-
Hospital St. Joseph, Marseille, FranceRecruitingPancreatitis, ChronicFrance